COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

doi:10.1016/j.autrev.2020.102683

. 2020 Dec;19(12):102683.

doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27.

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Víctor M Martínez-Taboada¹, Marcos López-Hoyos², Javier Crespo³, José L Hernández⁴

Affiliations

¹ Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.
² Division of Immunology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain. Electronic address: marcos.lopez@scsalud.es.
³ Division of Gastroenterology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.
⁴ Department of Internal Medicine, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.

PMID: 33127600
PMCID: PMC7588795
DOI: 10.1016/j.autrev.2020.102683

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Víctor M Martínez-Taboada et al. Autoimmun Rev. 2020 Dec.

. 2020 Dec;19(12):102683.

doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27.

Authors

Víctor M Martínez-Taboada¹, Marcos López-Hoyos², Javier Crespo³, José L Hernández⁴

Affiliations

¹ Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.
² Division of Immunology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain. Electronic address: marcos.lopez@scsalud.es.
³ Division of Gastroenterology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.
⁴ Department of Internal Medicine, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain.

PMID: 33127600
PMCID: PMC7588795
DOI: 10.1016/j.autrev.2020.102683

No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Cited by

Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection.
Sood A, Raghavan S, Batra P, Sharma K, Talwar A. Sood A, et al. Med Hypotheses. 2021 Nov;156:110681. doi: 10.1016/j.mehy.2021.110681. Epub 2021 Sep 20. Med Hypotheses. 2021. PMID: 34601231 Free PMC article.
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?
Ghasemzadeh M, Ahmadi J, Hosseini E. Ghasemzadeh M, et al. Thromb Res. 2022 May;213:179-194. doi: 10.1016/j.thromres.2022.03.022. Epub 2022 Mar 31. Thromb Res. 2022. PMID: 35397313 Free PMC article. Review.

References

1. Sarzi-Puttini P., Marotto D., Antivalle M. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: an expert opinion. Autoimmun Rev. 2020;19(7):102574. - PMC - PubMed
1. Ehrenfeld M., Tincani A., Andreoli L. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. - PMC - PubMed
1. Del Papa N., Sambataro G., Minniti A., Pignataro F., Caporali R. Novel COronaVirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev. 2020;19(7):102558. - PMC - PubMed
1. Khan N., Patel D., Xie D., Lewis J., Trivedi C., Yang Y.X. Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a Nationwide VA cohort study. Gastroenterology. 2020;159(4):1545–1546. [published online ahead of print, 2020 May 29] (S0016-5085(20)34737-5) - PMC - PubMed
1. Brenner E.J., Ungaro R.C., Gearry R.B. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020 doi: 10.1053/j.gastro.2020.05.032. [published online ahead of print, 2020 May 18] - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Sarzi-Puttini P., Marotto D., Antivalle M. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: an expert opinion. Autoimmun Rev. 2020;19(7):102574. - PMC - PubMed

[2] Sarzi-Puttini P., Marotto D., Antivalle M. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: an expert opinion. Autoimmun Rev. 2020;19(7):102574. - PMC - PubMed

[3] Ehrenfeld M., Tincani A., Andreoli L. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. - PMC - PubMed

[4] Ehrenfeld M., Tincani A., Andreoli L. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19(8):102597. - PMC - PubMed

[5] Del Papa N., Sambataro G., Minniti A., Pignataro F., Caporali R. Novel COronaVirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev. 2020;19(7):102558. - PMC - PubMed

[6] Del Papa N., Sambataro G., Minniti A., Pignataro F., Caporali R. Novel COronaVirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev. 2020;19(7):102558. - PMC - PubMed

[7] Khan N., Patel D., Xie D., Lewis J., Trivedi C., Yang Y.X. Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a Nationwide VA cohort study. Gastroenterology. 2020;159(4):1545–1546. [published online ahead of print, 2020 May 29] (S0016-5085(20)34737-5) - PMC - PubMed

[8] Khan N., Patel D., Xie D., Lewis J., Trivedi C., Yang Y.X. Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a Nationwide VA cohort study. Gastroenterology. 2020;159(4):1545–1546. [published online ahead of print, 2020 May 29] (S0016-5085(20)34737-5) - PMC - PubMed

[9] Brenner E.J., Ungaro R.C., Gearry R.B. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020 doi: 10.1053/j.gastro.2020.05.032. [published online ahead of print, 2020 May 18] - DOI - PMC - PubMed

[10] Brenner E.J., Ungaro R.C., Gearry R.B. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020 doi: 10.1053/j.gastro.2020.05.032. [published online ahead of print, 2020 May 18] - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Affiliations

COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical